KENILWORTH, N.J., Dec. 14 /PRNewswire-FirstCall/ -- Schering-Plough Corporation today announced that Ted Lithgow, Ph.D., has been appointed group vice president, commercial development, effective immediately. Dr. Lithgow most recently served as vice president, commercial development, Global Pharmaceutical Business.
In this role, Dr. Lithgow will coordinate the interaction between the Global Pharmaceutical Business (GPB), Schering-Plough Research Institute (SPRI) and the Global Supply Chain organizations to develop and commercialize the company's product pipeline. Also as part of his new role, he will be a member of the Global Pharmaceutical Business Management Team, chaired by Carrie Cox, executive vice president and president, Global Pharmaceuticals. He reports to Cox and will be responsible for achieving effective collaboration across the organization and ensuring that the company makes the best use of resources in creating value for patients, health care providers and other stakeholders. Dr. Lithgow will also be responsible for providing product profile direction to senior management at SPRI. He will also serve as the key liaison with Global Licensing to facilitate the valuation and assessment of in-licensing projects.
Dr. Lithgow has more than 20 years of experience in both the pharmaceutical and consumer health care industries. Prior to joining Schering-Plough in 2003, he was vice president, commercial development operations and emerging technologies at Pharmacia.
In his career, he has also held leadership positions in commercial development, research and development, and marketing at Warner-Lambert and Wyeth. Dr. Lithgow holds a B.A. degree in biology and psychology from Muhlenberg College, Allentown, Pa., an M. Phil. in biopsychology from The City University of New York, Jamaica, N.Y., and a Ph.D. in psychopharmacology from The City University of New York and Albert Einstein College of Medicine, Bronx, N.Y.
Schering-Plough is a global science-based health care company with leading prescription, consumer and animal health products. Through internal research and collaborations with partners, Schering-Plough discovers, develops, manufactures and markets advanced drug therapies to meet important medical needs. Schering-Plough's vision is to earn the trust of the physicians, patients and customers served by its more than 30,000 people around the world. The company is based in Kenilworth, N.J., and its Web site is http://www.schering-plough.com/.
CONTACT: Media Contact, Steve Galpin, Jr., +1-908-298-7415, or InvestorContacts, Janet Barth or Alex Kelly, +1-908-298-7436, all of Schering-PloughCorporation